Hims & Hers Shares Surge 12% Following HHS Secretary RFK Jr.’s Directive to Loosen Peptide Injection Restrictions

Hims & Hers Health Inc. shares jumped 12% after Health Secretary Robert F. Kennedy Jr. announced plans to ease restrictions on popular peptide injections.

By: AXL Media

Published: Apr 16, 2026, 8:54 AM EDT

Source: Bloomberg

The Regulatory Pivot and Market Reaction Hims & Hers Health Inc. (HIMS) saw its shares climb as much as 12% during Wednesday’s trading session, a direct response to a major policy announcement from the Department of Health and Human Services (HHS). Secretary Robert F. Kennedy Jr. utilized social media to signal a departure from previous restrictive stances regarding peptide injections. Peptides, which are used for a variety of health and wellness applications including weight management and hormone optimization, have occupied a contentious regulatory space. The market’s bullish reaction reflects investor optimism that Hims & Hers—a leader in the telehealth and direct-to-consumer pharmaceutical space—will be a primary beneficiary of a broader legal market for these compounds.

Restoring Regulated Access to Counter Black Markets In a statement published on X (formerly Twitter), Secretary Kennedy characterized the move as a return to "science, accountability, and the rule of law." He argued that previous restrictions had inadvertently fueled a dangerous black market, where consumers often turn to unverified sources for popular injectable treatments. By loosening these federal constraints, the HHS intends to shift consumer demand back toward regulated pharmaceutical providers and compounding pharmacies. This strategic pivot suggests a more permissive era for the "biohacking" and wellness industries, which have long sought more flexible pathways for peptide distribution.

Strategic Positioning for Telehealth Giants The development provides a significant tailwind for Hims & Hers, a company that has built its business model on making specialized treatments more accessible through digital platforms. Until now, the regulatory uncertainty surrounding certain peptides limited the scale at which telehealth companies could offer these injections. With the Secretary of Health and Human Services explicitly backing "regulated access," Hims & Hers is strategically positioned to integrate these high-demand treatments into its existing subscription-based ecosystem. Analysts view this as an opportunity for the company to diversify its portfolio beyond its core hair loss and sexual health categories.

Antitrust and Competitive Dynamics in the Wellness Sector This regulatory shift could disrupt the competitive landscape currently dominated by large pharmaceutical...